Back to Search
GREGORY RIELY, MD
MD
Medical Oncology Physician
NPI: 1770648875IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
228564(NY)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
228564(NY)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
CLVLND CLINIC LERNER COLLEGE OF MED OF CASE WSTN RSV UNIVERSITY
Class of 2001
Research & Publications (20)
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
PMID 19047285·J Clin Oncol·2009
3-trial
KRAS mutations: an old oncogene becomes a new predictive biomarker.
PMID 18832458·J Mol Diagn·2008
8-other
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
PMID 18794081·Clin Cancer Res·2008
8-other
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
PMID 18520300·J Thorac Oncol·2008
6-review
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
PMID 18513580·Lung Cancer·2008
6-review
Vascular endothelial growth factor trap in non small cell lung cancer.
PMID 17671153·Clin Cancer Res·2007
6-review
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
PMID 17785570·Clin Cancer Res·2007
8-other
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
PMID 17092603·Lung Cancer·2007
3-trial
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
PMID 16467097·Clin Cancer Res·2006
3-trial
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
PMID 17189394·Clin Cancer Res·2006
6-review
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
PMID 16294020·Cancer Biol Ther·2005
8-other
Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer.
PMID 19561260·Radiology·2009
8-other
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
PMID 19671843·Clin Cancer Res·2009
8-other
Comparison of patterns of relapse in thymic carcinoma and thymoma.
PMID 19577051·J Thorac Cardiovasc Surg·2009
4-observational
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.
PMID 18594331·J Thorac Oncol·2008
5-case
KRAS mutational testing in the selection of patients for EGFR-targeted therapies.
PMID 19013894·Semin Diagn Pathol·2008
6-review
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
PMID 19010870·Clin Cancer Res·2008
5-case
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
PMID 18981003·Clin Cancer Res·2008
8-other
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (646) 227-3275
Quick Facts
- NPI
- 1770648875
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 25
- Publications
- 20
Are you this provider?
Claim Your Profile